Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26360164 | 0.88 | — | — | |
| SCHEMBL24616618 | 0.74 | PIK3CD (0.31) | PIK3CD | |
| SCHEMBL25946573 | 0.74 | THRA (0.31) | PIK3CD | |
| SCHEMBL25204816 | 0.72 | EPHX2 (0.34) | — | |
| SCHEMBL26907193 | 0.72 | EPHX2 (0.34) | — | |
| SCHEMBL23022583 | 0.72 | PIK3CD (0.43) | PIK3CD | |
| SCHEMBL23022588 | 0.72 | PIK3CD (0.43) | PIK3CD | |
| SCHEMBL2443414 | 0.71 | NOS3 (0.33) | — | |
| Ammonia Solution, Strong SCHEMBL1894154 | 0.71 | — | — | |
| SCHEMBL23637950 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162197-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. | 2022-05-26 | — | — | US | disclosed |
| WO-2020081257-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-04-23 | — | — | WO | disclosed |
| US-20170304305-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | XUANZHU PHARMA CO LTD (CN) | 2017-10-26 | — | — | US | disclosed |
| US-20130053577-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20120190866-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-8178491-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100063071-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | BIOGEN IDEC MA INC. | 2010-03-11 | — | — | US | disclosed |
| US-20090257978-A1 | Antiviral coumpounds | GILEAD SCIENCES, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090047252-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20080004293-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC INC. | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162197-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | PIK3CD 2579/4885 |
| US-20170304305-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | NQO2, CHRM1, CHRM2 | PIK3CD 2700/4885 |
| US-20090257978-A1 | Antiviral coumpounds | MAVS, ZC3HAV1, EIF2AK2 | PIK3CD 2118/4885 |
| US-20130053577-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | PIK3CD 1022/4885 |
| US-20090186869-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | PIK3CD 1022/4885 |
| US-20120190866-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | PIK3CD 1022/4885 |
| US-20100063071-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | ADORA2A, P2RX3, P2RX6 | PIK3CD 1862/4885 |
| US-20090047252-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | PIK3CD 1022/4885 |
| US-20080004293-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | ADORA1, ADORA2A, ADORA3 | PIK3CD 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.